Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04877522 · ClinicalTrials.gov registry record · Phase 4

Asciminib Roll-over Study

A Phase 4 study of Chronic Myelogenous Leukemia and Leukemia, Myelogenous, Chronic, BCR-ABL Positive, sponsored by Novartis Pharmaceuticals.

Recruiting
Registry status
Phase 4
Development phase
347
Enrollment target
20
Study locations

NCT04877522 is a Phase 4 study of Chronic Myelogenous Leukemia and Leukemia, Myelogenous, Chronic, BCR-ABL Positive that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 347 participants, above the 271-participant average among 29 other Chronic Myelogenous Leukemia trials with a reported enrollment target (28% higher). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04877522, a Phase 4 study of Chronic Myelogenous Leukemia and Leukemia, Myelogenous, Chronic, BCR-ABL Positive, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.

RECRUITING
Registry status
Phase 4
Development phase
347 participants
Enrollment target
20
Study locations

Study Summary

This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment

Conditions Studied

Chronic Myelogenous Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Interventions

  • DRUG Dasatinib
  • DRUG Bosutinib
  • DRUG Nilotinib
  • DRUG Asciminib single agent
  • DRUG Imatinib

Study Locations (20)

Other

  • Novartis Investigative Site - Capital Federal
  • Novartis Investigative Site - Graz
  • Novartis Investigative Site - Vienna
  • Novartis Investigative Site - Varna

Texas

  • Texas Oncology - Dallas
  • Uni Of TX MD Anderson Cancer Cntr - Houston

São Paulo

  • Novartis Investigative Site - São Paulo
  • Novartis Investigative Site - São Paulo

Michigan

  • Michigan Med University of Michigan - Ann Arbor

New York

  • Memorial Sloan Kettering - New York

Oregon

  • Oregon Health Sciences University - Portland

Buenos Aires

  • Novartis Investigative Site - CABA

Rio de Janeiro

  • Novartis Investigative Site - Rio de Janeiro

Trial Details

FieldValue
Enrollment Target 347 participants
Start Date 2022-08-30
Est. Completion 2030-08-30
Phase Phase 4

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04877522

The ClinicalTrials.gov registry entry for NCT04877522 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 347 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 271-participant average among 29 other Chronic Myelogenous Leukemia trials with a reported enrollment target (28% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Chronic Myelogenous Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Dasatinib is the first listed.

NCT04877522 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, Texas, São Paulo.

Frequently Asked Questions

What is clinical trial NCT04877522 about?

NCT04877522 is a clinical study titled "Asciminib Roll-over Study". This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment

What is the current status of trial NCT04877522?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 347 participants. The study started on 2022-08-30. Estimated completion is 2030-08-30.

What conditions does trial NCT04877522 study?

This clinical trial studies the following conditions: Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

What interventions are being tested in trial NCT04877522?

The interventions under investigation include: Dasatinib (DRUG), Bosutinib (DRUG), Nilotinib (DRUG), Asciminib single agent (DRUG), Imatinib (DRUG).

Who is sponsoring clinical trial NCT04877522?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04877522 being conducted?

This trial has 20 study locations across Michigan, New York, Oregon, Texas, Buenos Aires. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Myelogenous Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Myelogenous Leukemia

All registered trials for this condition

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.